Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness, will host an investor webinar on October 30, 2025 at 4:15 PM EST (1:15 PM PST) to discuss a Regulation D 506(c) offering targeting US$5.0 million to expand distribution of unbuzzd, a beverage the company says accelerates alcohol metabolism and reduces hangover symptoms. The release states that Quantum shareholders will not be diluted by this offering and that the offering is for accredited investors only. Webinar speakers include Unbuzzd CEO John Duffy, Medical Director Dr. Eric Hoskins, Advisor Jason Sawyer, and Board Co-Chair Gerry David. A replay is available on request via investor@unbuzzd.com.
Summary not available.
Summary not available.
Quantum BioPharma (NASDAQ:QNTM) presents a hybrid issuer model combining neuroscience drug development, consumer-health commercialization, and market-access technology to create a "digital balance-sheet framework."
Key elements: flagship neuroprotective program Lucid-MS (Lucid-21-302), a PET imaging collaboration with Massachusetts General Hospital to track remyelination, a consumer brand Celly Nu with the unbuzzd beverage (royalty: 7% until $250M paid, then 3% in perpetuity), and a dual listing on Upstream approved in January 2025 to enable near-instant settlement and broader investor access.